期刊
IMMUNOLOGIC RESEARCH
卷 27, 期 2-3, 页码 185-202出版社
HUMANA PRESS INC
DOI: 10.1385/IR:27:2-3:185
关键词
CD 154; CD40-ligand; transcription; CD4 T cells; human; autoimmunity; transfection; systemic lupus erythematosus; hyper-IgM syndrome; atherosclerosis
类别
资金
- NIAID NIH HHS [P30-AI45008] Funding Source: Medline
- NICHD NIH HHS [P30-HD28815] Funding Source: Medline
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028815] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008] Funding Source: NIH RePORTER
CD154 (CD40-ligand) has a wide variety of pleiotropic effects Children's Hospital of throughout the immune system and is critical to both cellular and humoral immunity. Cell surface and soluble CD154 are primarily expressed by activated CD4 T cells. Expression of CD 154 is tightly regulated in a time-dependent manner, and, like most T cell-derived cytokines and other members of the tumor necrosis factor (TNF) superfamily, CD 154 is largely regulated at the level of gene transcription. Recently, dysregulated expression of CD154 has been noted in a number of autoimmune disorders, including systemic lupus erythematosus (SLE). In addition, abnormal expression of CD 154 has been hypothesized to contribute to a wider array of diseases, from atherosclerosis to Alzheimer's disease. Until recently, very little was known about the transcriptional regulation of CD 154. We are exploring CD 154 regulation in primary human CD4 T cells in hopes of understanding the cis- and traps-regulatory elements that control its expression in the cells that normally express CD 154. Ultimately, we hope to be able to correct abnormal expression of CD154 in various disease states and to help design gene therapy vectors for treating CD 154-deficient individuals with hyper-IgM syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据